<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="1ED30F09-EF21-8405-F560-B5855ACB2166" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">psorcon<sup>&#174;</sup> ointment<br />brand of diflorasone diacetate 0.05%</title>
<effectiveTime value="20060206" />
<setId root="29C78A72-3DDE-493F-B6A2-F286BEC1F09E" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Dermik Laboratories, Inc.</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="8B7653E3-BA66-37AF-54DE-2CB96BE0589A" />
<effectiveTime value="20060206" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0066-0071" codeSystem="2.16.840.1.113883.6.69" />
<name>Psorcon</name>
<formCode code="C42966" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OINTMENT" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="0.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="0.5" />
</numerator>
<denominator unit="g" value="1">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="7W2J09SCWX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>diflorasone diacetate</name>
<activeMoiety>
<activeMoiety>
<code code="T2DHJ9645W" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>diflorasone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>diflorasone diacetate</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylene glycol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>glyceryl monostearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>white petrolatum</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="g" value="60">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="60" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0066-0071-60" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="4DB932BB-A547-D1B6-3714-3F8F26CD1AA4" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph><content styleCode="bold">Not For Ophthalmic Use</content></paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="C0D9B4C5-3E0F-A24E-96F6-FF30F6903060" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>Each gram of <content styleCode="bold">psorcon</content> Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is 6&#945;,9-difluoro-11&#946;,17,21-trihydroxy-16&#946;-methylpregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is represented below:</paragraph><renderMultiMedia referencedObject="MM1" /><paragraph>Each gram of <content styleCode="bold">psorcon</content> Ointment contains 0.5 mg diflorasone diacetate in an ointment base of propylene glycol, glyceryl monostearate and white petrolatum.</paragraph></text>
<effectiveTime value="20060206" />
<component>
<observationMedia ID="MM1">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="psor-image01.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="2E53681A-4E17-1D19-ECA2-3A695BA8BEA0" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.</paragraph><paragraph>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizablecorrelation exists between vasoconstrictor potency and therapeutic efficacy in man.</paragraph></text>
<effectiveTime value="20060206" />
<component>
<section>
<id root="DA172A6A-04EC-99FF-0F0E-B2C3FC4713EA" />
<code code="43682-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PHARMACOKINETICS SECTION" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
<text><paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</paragraph><paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See <linkHtml href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</linkHtml>.)</paragraph><paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="34BFE68D-1290-3F33-A97A-1A67FC02FA83" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="E63E6CF9-D52D-2E6B-F369-5850820889B4" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section ID="PRECAUTIONS">
<id root="152DE8CB-CF51-C72B-4E53-399B8BB1EA68" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text />
<effectiveTime value="20060206" />
<component>
<section>
<id root="F3C64606-00E0-A97D-D367-F636A499CF49" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.</paragraph><paragraph>Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.</paragraph><paragraph>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</paragraph><paragraph>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</paragraph><paragraph>Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See <linkHtml href="#Pediatric_Use">PRECAUTIONS  Pediatric Use</linkHtml>.)</paragraph><paragraph>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</paragraph><paragraph>In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="0DEDE71D-5E45-1957-40F7-914FFEC4CFD6" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INFORMATION FOR PATIENTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Information For The Patients</title>
<text><paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph><list listType="ordered"><item>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</item><item>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</item><item>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</item><item>Patients should report any signs of local adverse reactions especially under occlusive dressing.</item><item>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on an infant or child being treated in the diaper area, as these garments may constitute occlusive dressings.</item></list></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="E993FA2F-5553-F090-296C-F01EDADE902B" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text><paragraph>The following tests may be helpful in evaluating the HPA axis suppression:</paragraph><paragraph>&#160;&#160;Urinary free cortisol test</paragraph><paragraph>&#160;&#160;ACTH stimulation test</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="54EF3D3B-6DE6-48B8-7047-7BFC01383DD8" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY SECTION" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, And Impairment Of Fertility</title>
<text><paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</paragraph><paragraph>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="0B8C5DBF-602E-9152-09D5-BAC8B6394976" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY SECTION" />
<title mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text><paragraph>Corticosteroids are generally teratogenic in laboratory animals when
administered systemically at relatively low dosage levels. The more potent corticosteroids have
been shown to be teratogenic after dermal application in laboratory animals. There are no
adequate and well-controlled studies in pregnant women on teratogenic effects from topically
applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if
the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used
extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="C6AC31C0-8585-C355-39CB-D07391826B1F" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>It is not known whether topical administration of corticosteroids could result in
sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered
corticosteroids are secreted into breast milk in quantities <content styleCode="bold">not</content> likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section ID="Pediatric_Use">
<id root="65AF76FD-6E50-E221-7479-1395F0422178" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness of <content styleCode="bold">psorcon</content> (diflorasone diacetate ointment) in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in pediatric patients.</paragraph><paragraph>HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol
levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension
include bulging fontanelles, headaches, and bilateral papilledema.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="468B31BE-BA9A-83A5-240E-8112CB4AF3C6" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>The following local adverse reactions have been reported with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:</paragraph><list listType="ordered"><item>Burning</item><item>Itching</item><item>Irritation</item><item>Dryness</item><item>Folliculitis</item><item>Hypertrichosis</item><item>Acneiform eruptions</item><item>Hypopigmentation</item><item>Perioral dermatitis</item><item>Allergic contact dermatitis</item><item>Maceration of the skin</item><item>Secondary infection</item><item>Skin atrophy</item><item>Striae</item><item>Miliaria</item></list></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="B3C6CE02-192C-B83E-68B4-4D05D54097E0" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See <linkHtml href="#PRECAUTIONS">PRECAUTIONS</linkHtml>.)</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section ID="DOSAGE_AND_ADMINISTRATION">
<id root="86D9C356-98E5-6E7D-1C5B-FC9F09D5B403" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph><content styleCode="bold">psorcon</content> Ointment should be applied to the affected area as a thin film from one to three times daily depending on the severity or resistant nature of the condition.</paragraph><paragraph>Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.</paragraph><paragraph>If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="EBCE946B-70CA-7797-47A2-2174936F561A" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph><content styleCode="bold">Psorcon</content> Ointment 0.05% is available in the following size tubes:</paragraph><table width="50%"><col align="center" width="50%" />
<col align="center" width="50%" />
<tbody>
<tr><td>60 gram</td><td>NDC 0066-0071-60</td></tr>
</tbody>
</table><paragraph>Store at controlled room temperature, 20&#176; to 25&#176; C (68&#176; to 77&#176; F) [see USP].</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="2F0D4AA6-154F-B129-D833-6A02E219CA31" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph><content styleCode="bold">Rx only</content></paragraph><paragraph>Manufactured by<br />Pharmacia &amp; Upjohn Company<br />A Division of Pfizer Inc<br />Kalamazoo, MI, USA 49001<br />For<br /><content styleCode="bold">Dermik Laboratories, Inc.</content><br />Berwyn, PA USA 19312<br /><br />50065610<br />813 377 212<br />691694<br />December 2001</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</structuredBody>
</component>
</document>
